Sign in
4

Changes in Ownership

Alkermes plc. Filed Acc 0001127602-25-002645

EVP R&D, Chief Medical Officer sold 100,918 shares at $32.05 ($3,234,382)

  • EVP R&D, Chief Medical Officer acquired 97,632 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hopkinson Craig C. · EVP R&D, Chief Medical Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2025-01-30 Exercise or conversion : show line 1 in the form 10b5-1 +29,156 $20.03 $583,995 76,732 D
2025-01-30 Exercise or conversion : show line 2 in the form 10b5-1 +26,589 $19.34 $514,231 103,321 D
2025-01-30 Exercise or conversion : show line 3 in the form 10b5-1 +23,542 $24.59 $578,898 126,863 D
2025-01-30 Exercise or conversion : show line 4 in the form 10b5-1 +18,345 $26.82 $492,013 145,208 D
2025-01-30 Sale : show line 5 in the form 10b5-1 −100,918 $32.05 $3,234,382 44,290 D
Open-market sales · 100,918 sh · avg $32.05 · $3,234,382

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2025-01-30 Exercise or conversion : show line 6 in the form 10b5-1 Employee Stock Option (Right to Buy) −29,156 87,566 D
2025-01-30 Exercise or conversion : show line 7 in the form 10b5-1 Employee Stock Option (Right to Buy) −26,589 161,734 D
2025-01-30 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (Right to Buy) −23,542 106,758 D
2025-01-30 Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (Right to Buy) −18,345 92,271 D
Loading xslF345X05/form4.xml…